Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin
Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (6) · 600-609
DOI: 10.1111/apt.17371 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 10.01.2023. Verfasst von Rebecca W Zeng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Neoplasms, Metformin. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Background
Emerging data suggest that statins, aspirin and metformin may protect against hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited by heterogeneity and inclusion of studies without adequate adjustment for baseline risks.
Aim
To examine by an updated meta‐analysis the association between these medications and HCC risk.
Methods
Medline and Embase databases were searched from inception to March 2022 for studies that balanced baseline risks between study groups via propensity score matching or inverse probability of treatment weighting, that reported the impact of statins, aspirin or metformin on HCC risk. Multivariable‐adjusted hazard ratios (HRs) for HCC were pooled using a random effects model.
Results
Statin use was associated with reduced HCC risk overall (HR: 0.52; 95% CI: 0.37–0.72) (10 studies, 1,774,476), and in subgroup analyses for cirrhosis, hepatitis B/C, non‐alcoholic fatty liver disease, studies accounting for concurrent aspirin and metformin consumption and lipophilic statins. Aspirin use was associated with reduced HCC risk overall (HR: 0.48; 95% CI: 0.27–0.87) (11 studies, 2,190,285 patients) but not in studies accounting for concurrent statin and metformin use. Metformin use was not associated with reduced HCC risk overall (HR: 0.57; 95% CI: 0.31–1.06) (3 studies, 125,458 patients). Most analyses had moderate/substantial heterogeneity, except in follow‐up
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
- National University Centre for Organ Transplantation, National University Health System, Singapore, Singapore.
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- The Catholic University Liver Research Centre, Seoul, Korea.
ORCID-Profile: Nicholas Syn, Mark D Muthiah, Cheng Han Ng, Beom Kyung Kim, Mindie H Nguyen, Rohit Loomba, Daniel Q Huang
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIEHS NIH HHS
- NIAAA NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Zeng, R. W., Yong, J. N., Tan, D. J. H., Fu, C. E., Lim, W. H., Xiao, J., Chan, K. E., Tan, C., Goh, X. L., Chee, D., Syn, N., Tan, E. X., Muthiah, M. D., Ng, C. H., Tamaki, N., Lee, S. W., Kim, B. K., Nguyen, M. H., Loomba, R., & Huang, D. Q. (2023). Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology & Therapeutics, 57(6), 600-609. https://doi.org/10.1111/apt.17371
Vancouver
Zeng RW, Yong JN, Tan DJH, Fu CE, Lim WH, Xiao J, et al. Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Alimentary Pharmacology & Therapeutics. 2023;57(6):600-609. doi:10.1111/apt.17371
BibTeX
@article{Zeng2023,
author = {Zeng, Rebecca W and Yong, Jie Ning and Tan, Darren J H and Fu, Clarissa E and Lim, Wen Hui and Xiao, Jieling and Chan, Kai En and Tan, Caitlyn and Goh, Xin Lei and Chee, Douglas and Syn, Nicholas and Tan, Eunice X and Muthiah, Mark D and Ng, Cheng Han and Tamaki, Nobuharu and Lee, Sung Won and Kim, Beom Kyung and Nguyen, Mindie H and Loomba, Rohit and Huang, Daniel Q},
title = {Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {6},
pages = {600--609},
doi = {10.1111/apt.17371}
}
EUVIMED